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Background: Serum lipid profile changes have been observed during malaria infection. The underlying biological
mechanisms remain unclear. The aim of this paper is to provide an overview on those serum lipid profile changes,
and to discuss possible underlying biological mechanisms and the role of lipids in malaria pathogenesis.
Methods: A systematic review and meta-analysis to determine lipid profile changes during malaria was conducted,
following PRISMA guidelines. Without language restrictions, Medline/PubMed, Embase, Cochrane Central Register of
Controlled Trials, Web of Science, LILACS, Biosis Previews and the African Index Medicus were searched for studies
published up to 11 July, 2013, that measured serum lipid parameters in malaria patients. Also, major trial registries were
searched. Mean differences in lipid profile parameters were combined in fixed and random effects meta-analysis, with
a separate analysis for different groups of controls (healthy, other febrile illnesses or very low parasitaemia). These
parameters were also compared between severe malaria and uncomplicated malaria. Funnel plots were used to test
for publication bias.
Results: Of 2,518 studies reviewed, 42 met the criteria for inclusion in the qualitative analysis, and of these, 15 reported
the necessary data for inclusion in the meta-analysis for cholesterol; nine for high-density lipoprotein (HDL), eight for
low-density lipoprotein (LDL), and nine for triglycerides, respectively. Total cholesterol, HDL and LDL concentrations
were lower in malaria and other febrile diseases compared to healthy controls. The decline was more pronounced and
statistically significant during malaria compared to other febrile diseases. These results were consistent across included
studies. Triglycerides were raised compared to healthy controls, but not statistically significant when compared to
symptomatic controls.
Conclusions: This meta-analysis suggests that the observed lipid profile changes are characteristic for malaria. Although
a definite link with the pathogenesis of malaria cannot yet be demonstrated, plausible hypotheses of biological
mechanisms involving host lipid alterations and the pathogenesis of malaria exist. An increased research effort to
elucidate the precise pathways is warranted, since this could lead to better understanding of malaria pathophysiology
and consequently to novel treatment approaches.
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Patients with malaria often exhibit laboratory abnormal-
ities due to an acute phase response, but little is known
about serum lipid profile changes in malaria. In 1978,
Lambrecht et al. [1] reported transient lipid profile
changes in six returning travellers with malaria caused
by Plasmodium vivax and suggested for the first time
that changes in high-density lipoprotein (HDL) and very
low-density lipoprotein (VLDL) in human serum are re-
lated to the lipid metabolism of the parasite. It was hy-
pothesized that the malaria parasite uses cholesterol and
phospholipids from its host, resulting in a decrease of
serum HDL. Prior to this report, Angus et al. [2-4] uti-
lized lipoprotein electrophoresis in rhesus monkeys in-
fected with Plasmodium knowlesi to study serum lipids
in malaria. Their results were not conclusive because
lipoprotein bands could barely be detected in the serum of
controls. Subsequently, several clinical studies showed
lipid profile changes in the setting of both uncomplicated
and complicated malaria [5-10]. Although the magnitude
of changes seems to be related to the severity of malaria in
several studies [11,12], others found no correlation be-
tween the severity of malaria attacks and the extent of
lipid profile changes [13,14]. These transient lipid profile
changes in the parasitaemic phase have been suggested by
some researchers as a potential adjuvant diagnostic tool
for malaria [13,15,16].
Changes in serum lipid profile and lipid metabolism are
due to a whole range of at least partially disease-specific
mechanisms [17]. The extent of serum lipid profile
changes during malaria infection and their underlying bio-
logical mechanisms remain unclear. Mechanisms may be
partly host related (i e, related to an acute phase reaction
[18]), parasite-related [19-21], or a combination of these
two. If a link between human host serum lipid alterations
and the pathogenesis of malaria can be demonstrated, fur-
ther studies to elucidate the precise pathways can be con-
ducted. Moreover, novel treatment approaches could be
explored with lipid metabolism-regulating drugs. There-
fore, it is hypothesized that the lipid profile of malaria ex-
hibits characteristic changes. In addition, it is understood
that these changes are specific for the malaria pathogen-
host interplay.
Objectives
The present systematic review aims at identifying serum
lipid profile changes in malaria with respect to com-
monly used laboratory parameters: (total) cholesterol
(TC), high-density lipoprotein cholesterol (HDL), low-
density lipoprotein cholesterol (LDL), very low-density
lipoprotein cholesterol (VLDL) and triglycerides (TG).
Also, intermediate density lipoproteins (IDL) and apo-
lipoproteins (all classes) are investigated. Furthermore,
different possible underlying biological mechanismsand the role of lipids in the pathogenesis of malaria
are discussed.
Methods
Methods of the present review, objectives and inclusion
criteria were specified in advance and documented in a
protocol (see Additional file 1) [22]. Recommendations
made by the Meta-analysis of Observational Studies in
Epidemiology (MOOSE) and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
groups [23-25] were followed. The electronic databases
Medline/PubMed (1946 to July 2013), Embase (via Ovid,
1947 to July 2013), Cochrane Central Register of Controlled
Trials (The Cochrane Library, 10 July 2013), Web of Sci-
ence (1975 to July 2013), LILACS (Latin-American and
Caribbean Health Sciences Literature; 1982 to July 2013),
Biosis Previews (1993 to July 2013) and the African Index
Medicus (1993 to July 2013) were searched in order to
identify studies published up to present. In addition, major
trial registries [26,27] were searched to identify ongoing or
future trials. The search strategy consisted of free-text
words and subject headings related to malaria and serum
lipids. The search strategy was not limited by study design
or language. The full search strategies for every searched
database are reported in Additional file 2. An experienced
clinical librarian (IMN) conducted the actual searches on 9,
10 and 11 July 2013. Bibliographies of relevant studies re-
trieved from the studies were checked for additional publi-
cations. Reference Manager 12.0.3 (Thomson Reuters) was
used to manage, de-duplicate and screen the references for
eligibility. Reports published before a certain point in time
were not excluded. Selection criteria for inclusion of re-
trieved studies were as follows; the study population con-
sisted of patients with malaria (Plasmodium falciparum,
Plasmodium ovale, P. vivax, Plasmodium malariae and P.
knowlesi) of all age groups. Also, at least one of the follow-
ing outcomes of interest was measured: a) TC; b) HDL; c)
LDL; d) IDL; e) VLDL; f) apolipoproteins (all classes); g)
TG. All types of studies, including cross-sectional, case–
control, case-report and cohort studies were included in
the qualitative analysis. To prevent bias, studies with and
without (healthy) controls were included. Animal studies
were excluded because it is doubtful whether animal studies
are comparable to humans regarding lipid profile changes
during malaria. Eligibility assessment of studies was per-
formed independently in an unblinded, standardized way
by two reviewers (BJV and RWW). Titles and abstracts
were screened first, and then one reviewer (BJV) screened
and selected relevant full-text articles. For quality control,
RWW reviewed 60 (50%) randomly selected full-text arti-
cles screened. One author (BJV) extracted the following
study characteristics: first author, year of publication, lan-
guage, study setting, study design, characteristics of trial
participants, type and number of controls, type of outcome
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poproteins) and, if provided, sensitivity/specificity and
positive- and negative predictive values. The time of meas-
urement of the outcomes of interest was at admission
(“Day 0”) and before anti-malarial treatment. Data was
double checked by RWW for all articles included (n = 42).
Disagreements in the selection process between reviewers
were resolved by consensus or on consultation with the se-
nior author (MPG). The study selection process is summa-
rized in the PRISMA flow diagram (see Figure 1). Authors
were not contacted for further information, or to confirm
the accuracy of information included in our review with the
original researchers, since for the majority of papers ad-
equate contact information was missing. Risk-of-bias as-
sessments for studies included in the quantitative synthesis
were made (see Additional file 3). No studies were excluded
on the basis of quality.
The existence of publication bias was investigated
using funnel plots [28]. A funnel plot is a scatter plot
of (treatment) effect against a measure of study size.
The risk of publication bias is most probably larger forFigure 1 Study selection (PRISMA flow diagram).observational studies than randomized controlled trials,
particularly small observational studies as included in
this present review [29]. For this reason, the overall pub-
lication bias risk for this systematic review is considered
as substantial.
Statistical analysis
Studies that met the eligibility criteria and that reported
means and standard deviation (SD), or presented sufficient
data for the calculation of means and/or SD, were in-
cluded in the meta-analysis. The inverse-variance method
for the meta-analysis, in which weight is given to each
study according to the inverse of the variance of the effect,
in order to minimize uncertainty about the pooled effect
estimates (see Additional file 4: Statistical analysis). The
studies included were allocated into four groups: choles-
terol, HDL, LDL, and triglycerides. Studies with healthy
controls and symptomatic controls were analysed separ-
ately. If studies presented results for uncomplicated as well
as for severe malaria [12,30,31], the combined data were
used (see Additional file 4). Stratified analyses for
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Additional file 5). Data were entered by RWW and
checked by BJV. Missing data were not problematic since
meta-regression of individual data was not done. The I2
and 95% CI were used to quantify heterogeneity. I2 repre-
sents the percentage of the total variation in estimated ef-
fects across studies, which is due to real heterogeneity
rather than to chance [23]. Initially a fixed effect meta-
analysis was performed; however, if I2 was large (>50%),
which suggests substantial heterogeneity, random-effects
analysis was used. Forest and funnel plots were produced
to visually assess the mean difference(s) and SD of each
study (see Additional file 6). Analyses were done with Rev-
Man 5.2 (Review Manager 5.26. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2012).
Results
The initial search yielded 4,406 records of which 2,518
remained after removal of duplicates (see Figure 1). Forty-
two records [1,5-16,30-57] met the inclusion criteria
(Additional file 7: Table S1). Of these, n = 15 for choles-
terol [7,9,10,12,30,31,33,35,38,40,42,44,46,50,52,54]; nine
for HDL [10,12,30,33,35,38,42,44,52]; eight for LDL [10,12,
30,33,35,38,42,52]; nine for triglycerides [10,12,30,33,35,
40,42,50,52], contained the necessary data for inclusion in
the quantitative analysis (meta-analysis); see PRISMA flow
diagram (Figure 1). Four records [11,13,14,47] were ex-
cluded from the quantitative synthesis either because
means and SD were not reported (n = 3), or mean differ-
ences and SD could not be calculated from the available
data (n = 1). For one record, a case report [57], the full text
was not retrievable. The meta-analysis was done for chol-
esterol, HDL, LDL and triglycerides (see Additional file 6).
For other parameters, such as the apolipoproteins, IDL
and VLDL, there was insufficient data to perform a quan-
titative analysis. If only one study was to be included in
the meta-analysis, the forest plot is not shown. For each
outcome, two comparisons were made. The first compari-
son compared means of malaria cases with healthy con-
trols. The second comparison compared malaria cases
with symptomatic controls (malaria-like symptoms, but
negative for malaria). This second comparison is import-
ant as it can indicate whether alterations in lipid profile
parameters are malaria specific or also occur in other fe-
brile diseases.
Description of included studies
For all articles except one [57], the full text paper could
be retrieved. The majority of records was published in
English; however, 31% (13/42) were in another language
(of which French - 19%, 8/42; others 12%, 5/42). Eighty-
three percent (35/42) of the records were found using
only Medline/PubMed. Fourteen studies took place
in sub-Saharan Africa; ten in (Southeast) Asia; 16 inWestern countries (Europe, USA, Australia); and two in
South America. In total, 3,442 patients with malaria
were analysed in these studies, and compared with 1,686
controls (patients negative for malaria). Thirty-five were
adult studies and seven were paediatric studies [14,30,31,
36,44,52,55]. In 26 of these 42 records, serum lipid pro-
files of malaria patients were compared to a control
group. These control groups consisted of healthy con-
trols (15 studies) [7,9,11,12,14,30,31,33,38,40,44,47,50] or
“symptomatic” controls [16,35,37,44,46] (malaria-like symp-
toms but negative for malaria). There were two records
including controls with a (very) low parasitaemia [10,32];
one of these two [32] did not report the necessary data and
was therefore excluded from the meta-analysis; the other
study [10] was included in the meta-analysis for healthy
controls. A separate analysis was also performed without
this study [10]; these results are reported in Additional file
8. In four studies, both healthy controls and symptomatic
controls were recruited [13,35,44,46] and compared. In two
studies, the controls were not adequately described [41,42].
These two studies were considered as studies with healthy
controls. Reference values and measurement units varied
considerably among the included studies and were often
not reported.
Cholesterol
Serum total cholesterol was measured in 36 of 42 included
studies. 83% (30/36 studies) reported a hypocholesterolae-
mia in patients with malaria or a significantly lowered
total cholesterol level compared to the control group.
Two studies reported a raised cholesterol [36,41], three
studies showed no significant differences with the control
group [9,39,43] and one study was inconclusive [48] (see
Additional file 7: Table S1 for details). Forest plot 1 (n =
15) (Figure 2) shows the mean difference for cholesterol in
malaria patients versus healthy controls: 1.09 mmol/l or
42.15 mg/dl (95% CI 0.74-1.44 mmol/l), I2 = 98%, Z = 6.14
P < 0.00001. Forest plot 2 (n = 3) (Figure 3) shows the
mean difference for cholesterol in malaria patients versus
symptomatic controls: 0.79 mmol/l or 30.55 mg/dl (95%
CI 0.13-1.45 mmol/l), I2 = 90%, Z = 2.34, P = 0.02. Thus,
cholesterol is significantly decreased during malaria. For
severe malaria, a separate analysis including three studies
[12,30,31] was performed (Additional file 5). Mean differ-
ence for cholesterol in severe malaria patients versus
healthy controls was 1.60 mmol/l or 61.87 mg/dl (95% CI
0.66-2.54), I2 = 99%, Z = 3.33, P = 0.0009.
High-density lipoprotein (HDL)
In 23 of 42 studies HDL was measured during malaria.
Eighty-seven percent (20/23 studies) reported a large
decline in HDL-concentrations. Forest plot 3 (n = 9)
(Figure 4) shows the mean difference for HDL in malaria




















Heterogeneity: Tau² = 0.44; Chi² = 897.72, df = 14 (P < 0.00001); I² = 98%
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Figure 2 Forest plot Mean difference for cholesterol (mmol/l) between malaria patients and healthy controls. Random-effect model.
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Forest plot 4 (n = 2) (Figure 5) shows the mean difference
for HDL in malaria patients versus symptomatic controls:
0.39 mmol/l or 15.08 mg/dl (95% CI 0.07-0.72 mmol/l),
I2 = 85%, Z = 2.39, P = 0.02. Two studies [30,31] showed a
significant larger decline in HDL in severe malaria com-
pared to uncomplicated malaria. Thus, HDL is signifi-
cantly lower in malaria.
Low-density lipoprotein (LDL)
In 16 of 42 studies LDL was measured during malaria.
Eighty-one percent (13/16 studies) reported a lower
LDL-c concentration in malaria patients. Forest plot 5
(n = 8) (Figure 6) shows the mean difference for LDL in
malaria patients versus healthy controls: 0.82 mmol/l or
31.71 mg/dl (95% CI 0.24-1.39 mmol/l), I2 = 97%, Z =
2.79, P = 0.005. Only one study compared LDL in mal-
aria patients with symptomatic controls and found a dif-
ference of 1.67 mmol/l or 64.58 mg/dl (95% CI 1.44-
1.90 mmol/l), P < 0.01[35]. Two studies [30,31] showed a
significant larger decline in LDL in patients with severe
malaria compared to patients with uncomplicated mal-
aria. Thus, LDL is significantly lower in malaria.
Triglycerides
In 23 of 42 studies triglycerides were measured during
malaria. Seventy-eight percent (18/23 studies) reported ahypertriglyceridemia and/or a significantly higher mean
triglyceride plasma concentration in malaria patients
compared to controls. Forest plot 6 (n = 9) (Figure 7)
shows the mean difference for triglycerides in malaria pa-
tients versus healthy controls: 0.25 mmol/l or 22.14 mg/dl
(95% CI 0.12-0.37 mmol/l), I2 = 82%, Z = 3.79, P = 0.0002.
Forest plot 7 (n = 2) (Figure 8) shows the mean difference
for triglycerides in malaria patients versus symptomatic
controls: 0.42 mmol/l or 37.20 mg/dl (95% CI 0.46-
1.31 mmol/l), I2 = 95%, Z = 0.94, P = 0.35. Thus, triglycer-
ides are significantly higher in malaria patients compared
to healthy controls, but these differences become non-
significant when compared to symptomatic controls. In
patients with severe malaria triglyceride levels were found
to be higher compared to triglyceride levels in patients
with uncomplicated malaria [12,30].
Very low-density lipoprotein (VLDL)
Five studies measured VLDL during malaria, of which
one case report found marked bands of VLDL [6]. No
meta-analysis could be conducted due to insufficient
data. In a consecutive case-series in six patients with
P. vivax malaria, three of six patients had VLDL levels
below detection limits [1]. A small cross-sectional study
in returning travellers with malaria (n = 12) found a
raised plasma VLDL-c in nine of ten patients [8]. This






















Heterogeneity: Tau² = 0.30; Chi² = 19.81, df = 2 (P < 0.0001); I² = 90%
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Figure 3 Forest plot Mean difference for cholesterol (mmol/l) between malaria patients and symptomatic controls.
Random-effect model.
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group (n = not reported) which found a raised mean
concentration compared to the controls (p < 0.05) [41].
An observational study in French soldiers reported “no
significant difference found for VLDL” but did not re-
port means and p-values [9].
Intermediate-density lipoprotein (IDL)
None of the included studies measured or reported
intermediate-density lipoprotein (IDL) during malaria.
Apolipoproteins
Apolipoproteins were measured in five studies. No meta-
analysis could be conducted due to insufficient data. A pa-
tient with Tangier disease and P. falciparum was reported
to have apolipoprotein A1 levels below detection levels
[34]. A small cross-sectional study with 37 P. falciparum
patients and 37 healthy controls also found a decrease in
apoliprotein A in patients compared to controls, but a
higher concentration of apolipoprotein B in malaria pa-
tients [38]. Kittl et al. [13] observed apolipoprotein A and
A-1 lowered in malaria patients, and a very strong correl-
ation with HDL-c (r = 0.96 for Apo A and r = 0.95 for Apo
A-1). However, mean values for the malaria group and the
control group are not reported. No significant differencesbetween patients and controls for apolipoprotein A1, A2
or B were found by Cuisinier-Raynal [9]; however, mean
or p-values were not reported. A pilot descriptive pro-
spective cross-sectional study to investigate the link be-
tween nutrition and immunity in Colombian children
showed significantly lowered apolipoprotein A1 levels in
the malaria group compared to the healthy controls [55].
Duration of lipid profile changes
The time for malaria patients to recover from the serum
lipid profile alterations varied widely across studies.
Eight studies [8,10,12,15,34-36,39] reported measure-
ments after “day 0” (admission, before anti-malarial
treatment). In most studies, lipid parameters resolved
slowly; in one study levels of cholesterol, HDL and LDL
were significantly lower in the malaria patients than in
the control group at one month after treatment. Most
lipid levels had increased at six months while triglyceride
levels continued to be lower than normal parameters
[35]. These findings contrast with findings from a study
in travellers with malaria; both LDL and plasma trigly-
ceride concentrations were normalized at follow up after
2 weeks [15]. In a paediatric study, TC and HDL were
still decreased after two weeks, but triglycerides normal-
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Figure 4 Forest plot Mean difference for HDL (mmol/l) between malaria patients and healthy controls. Random-effect model.
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mal levels in ten days [46].
Quality assessment and publication bias
Overall quality assessment scores for risk of bias in stud-
ies included in the quantitative analysis ranged from one
to five, out of a maximum of five. All studies except one
[42] were observational studies. None of them was re-
ported according to all the criteria of the STROBE state-
ment (STrengthening the Reporting of OBservational
studies in Epidemiology) [58], a tool in observational
studies to prevent bias. In addition, none of the studies
that assessed one or more of the lipid profile changes as
diagnostic feature of malaria reported the essential infor-
mation according to the criteria of the STARD statement
(STAndards for the Reporting of Diagnostic accuracy
studies) [59], a tool to improve the accuracy and com-
pleteness of reporting for studies of diagnostic accuracy.
Visual assessment of funnel plots showed that the stud-
ies were distributed fairly symmetrically about the com-
bined effect size, which suggests little publication bias.
Discussion
This is the first systematic review and meta-analysis of
the impact of malaria on common lipid profile parame-
ters. It confirms previous studies that characteristic
serum lipid profile changes occur during malaria. Lowserum TC, a low HDL, a low LDL during malaria are de-
scribed as compared to reference values, healthy and
symptomatic controls. Triglycerides were raised during
malaria, but this was statistically not significant when
compared to symptomatic controls. The conclusion is
supported by a similar size and direction of lipid profile
changes noted in the records not included in the quanti-
tative synthesis (Additional file 7: Table S1). For IDL
cholesterol, VLDL and apolipoproteins, no robust alter-
ations could be observed due to complete absence and
paucity, respectively, of studies that measured these la-
boratory parameters.
The major difficulty regarding the clinically observed
serum lipid profile changes is whether they are not only
characteristic but truly specific for malaria, rather than a
general observed phenomenon that can also be seen in
other conditions, particularly (infectious) diseases. More-
over, the association between serum lipid profile changes
and malaria is not definitive evidence for the direction of
causality, since the existence of confounders, for ex-
ample, ethnicity, socio-economic status, life-style, food
habitats, other infections or diseases, etc., cannot be
ruled out and was not corrected for in most of the in-
cluded studies in this review.
Several arguments support the conclusion that the
lipid changes identified are indeed characteristic for mal-
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Figure 6 Forest plot Mean difference for LDL (mmol/l) between malaria patients and healthy controls. Random-effect model.
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Figure 8 Forest plot Mean difference for triglycerides (mmol/l) between malaria patients and symptomatic controls. Random-effect model.
Visser et al. Malaria Journal 2013, 12:442 Page 9 of 16
http://www.malariajournal.com/content/12/1/442
Visser et al. Malaria Journal 2013, 12:442 Page 10 of 16
http://www.malariajournal.com/content/12/1/442several plausible biological mechanisms are at hand (as
discussed in some detail below) that can cause these lipid
profile changes in malaria patients. Secondly, consistent
findings observed by different researchers in different
places with different samples are provided in this review
(see Additional file 7: Table S1). The fact that data repre-
sent studies that included local inhabitants as well as non-
immune travellers returning from the tropics, both adults
and children, indicates these findings are not ethnic-, age-
or geographically specific but observed in a variety of set-
tings and patients (see Additional file 7: Table S1). Results
also suggest that a biological gradient is present as greater
exposure (severe malaria) leads to greater incidence of the
effect (lipid profile changes), as shown in the stratified ana-
lysis for severe and uncomplicated malaria (see Additional
file 5). An important pre-requisite for causality is temporal-
ity: the lipid profile changes have to occur after malaria.
This, however, cannot be concluded from this meta-
analysis nor the included studies since the majority of the
included studies are cross-sectional (cause and effect mea-
sured at one specific point of time) or prospective observa-
tional studies with malaria present at the start of the study.
Inverse temporality is demonstrated; treatment of malaria
allows the lipid parameters to normalize. It remains to be
elucidated why prolonged lipid profile changes are ob-
served even after parasites have been cleared.
Since only controlled studies were included in the quan-
titative synthesis, other non-infectious diseases and gen-
etic factors are probably comparable among groups. This
supports lipid profile changes as malaria-characteristic
features; however, it does not exclude confounding. To in-
vestigate the main confounder, namely other infectious
diseases, studies that compare lipid profile changes during
malaria with control patients that present with other infec-
tious diseases are pivotal. The meta-analysis (Figures 3, 5
and 8) that included comparisons between malaria pa-
tients and symptomatic controls suggests that the ob-
served lipid profile changes are indeed specific for malaria.
TC, HDL and LDL concentrations were lower in malaria
and other febrile diseases compared to healthy controls,
however, the decline was more pronounced and statisti-
cally significant during malaria. If these lipid profile
changes are characteristic for malaria, one could expect
more pronounced lipid alterations in severe malaria com-
pared to uncomplicated malaria; this is confirmed by three
studies [12,30,42]. Biological mechanisms of lipid profile
changes may be partly host-related, i.e., related to an acute
phase reaction [18] or parasite-related [20] or a combin-
ation of these two.
Host-related lipid profile changes
Transient plasma lipid profile changes are not only ob-
served during malaria, but also in other acute diseases
[60,61]. Typically, HDL and LDL cholesterol levels areslightly reduced, and VLDL levels may be increased. Sev-
eral researchers demonstrated low cholesterol levels in
acute conditions such as surgical trauma [62], malig-
nancy [63], burns [64] and ischemic heart disease [18].
Hence the changes in plasma lipoproteins appear to
form part of the acute-phase reaction and can, at least
partially, be ascribed to extravasation due to increased
capillary permeability [65]. In addition, a decrease of TC
and triglycerides has been reported in patients admitted
with an acute infection [66,67]. In a study with critically
ill patients, the mean HDL level was significantly lower
in patients with an infection compared to patients with-
out infection [68]. The TC levels seemed to be slightly
lower and triglycerides higher in infected patients, but
these differences were not statistically significant [68].
Various forms of lipid disorders have been associated
with acute and chronic infectious diseases of different
aetiologies: bacterial, viral and parasitological [69-71]. In
human immunodeficiency virus (HIV) infection an in-
crease in the levels of triglycerides and reduced levels of
cholesterol, HDL-c and LDL-c [72-74] have been ob-
served. Moreover, the treatment of HIV with high-
activity, anti-retroviral therapy (HAART) can cause a
more atherogenic lipid profile by increased TC, LDL-c
and triglycerides [75]. Hypertriglyceridemia has been de-
scribed in several diseases with haemophagocytosis.
Hypocholesterolaemia has also been described in vari-
ous haematological diseases [76], including thalassaemia
major [77], thalassaemia intermedia [78], sickle cell dis-
ease [79], glucose-6-phosphate dehydrogenase (G6PD)
deficiency [80], spherocytosis [81], and aplastic anaemia
[82]. It can also accompany anaemia with high erythro-
poietic activity [83]. The pathophysiology of the lowered
cholesterol levels in these diseases remains obscure, al-
though several mechanisms have been proposed, includ-
ing the dilution of serum due to anaemia; increased
cholesterol needs associated with erythroid hyperplasia;
macrophage activation with the release of cytokines; in-
creased cholesterol uptake by the reticulo-endothelial
system; and liver injury secondary to iron overload [83].
Pathophysiological pathways of lipids during malaria
Lipids are synthesized in the liver, which incidentally hap-
pens to be the site where infective malaria sporozoites
travel through the bloodstream, invade and take up resi-
dence in the hepatocytes. In this asymptomatic ‘exo-
erythrocytic stage’ these cells divide until many mature
tissue schizonts are formed, each containing thousands of
merozoites. The liver schizonts rupture after days and re-
lease these merozoites into the bloodstream, initiating the
‘erythrocytic stage’. Within the erythrocyte, a single mero-
zoite divides into eight to 32 merozoites, which demands a
considerable amount of lipids (e g, cholesterol) for their
anabolic requirements such as membrane formation. The
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achieving one of the fastest growth rates among eukaryotic
cells [84]. Malaria parasites are intracellular protozoans,
auxotrophic and unable to synthesize organic nutrients
required for their growth. To ensure their survival and
propagation, they must exchange nutrients over the parasi-
tophorous vacuolar membrane (PVM) [85], which sur-
rounds the parasite [86,87]. This PVM neither acidifies nor
fuses with organelles of the endocytic cascade and exocytic
pathway and is thus actually completely isolated from the
host cell vesicular transport system [88].
Keeping this in view, the following questions arise.
First, what is the relation between malaria parasites and
lipid synthesis in the liver - are malaria parasites capable
to produce essential lipids themselves or are host lipids
required? Second, does the malaria parasite benefit from
high or low serum lipids in the host environment?
In order to meet the nutrients to rapidly multiply within
hepatocytes, but more importantly, red blood cells, mal-
aria parasites must scavenge host cell nutrients they
cannot synthesize. Plasmodium spp. cannot synthesize
cholesterol itself [89], similar to other intracellular patho-
gens. These pathogens most often possess the ability to ac-
cess this lipid from the exogenous or endogenous pathway
of the host [90-93]. Also, no biological pathway involved
in sterol production can be demonstrated in Plasmodium
spp. genome databases [94]. It must be said, however, that
morphological data suggest that the parasitophorous vacu-
ole of malaria liver forms does contain sterols [95].
Recent findings demonstrate that the Plasmodium
genome includes gene-encoding enzymes for phospho-
lipids metabolism [96], allowing de novo synthesis of
phosphatidylcholine via the Kennedy Pathway (de novo
synthesis of phosphatidylethanolamine and phosphat-
idylcholine) and necessitating only the uptake of the
small choline molecule [88]. This is important, because
these two account for more than 50% of the total
phospholipid species in eukaryotic membranes and thus
play a major role in the structure and function of those
membranes [97]. Moreover, the genome of P. falciparum
has genes similar to those encoding for the type II fatty
acid synthesis pathway in humans. The type II fatty acid
synthetic pathway is the principal route for the produc-
tion of membrane phospholipidacyl chains [98]. These
particular genes are embedded within the apicoplast
[99], and aid the production of fatty acids, some of
which are unique for Plasmodium spp. [88]. Therefore,
Plasmodium spp. might be able to meet several of its
lipid needs from its own biological pathways, even if
specific extracellular lipids are necessary for in vitro
growth [96]. The presence of cholesterol in apicoplast
membranes was shown only recently [100].
However, the inability of Plasmodium to stock up host
molecules makes a continuous supply of nutrients to theparasite necessary [94]. Probably, this is one of the rea-
sons that malaria parasites choose hepatocytes, as they
have unique metabolic properties and are especially effi-
cient in internalizing transport proteins (e. g, lipoproteins)
via membrane receptors and are proficient at metabolizing
different compounds (e. g, glucose, lipids etc.) in relatively
huge quantities [101-104].
A recent study shows that Plasmodium divert choles-
terol from the hepatocyte cell until the release of mero-
zoites. Removal of plasma lipoproteins in vitro resulted
in a 70% reduction of cholesterol content in hepatic
merozoites [94]. It was discovered that Plasmodium spp.
(P. yoelii and P. berghei) salvage cholesterol that had
been internalized by LDL. However, reduced expression
of host LDL receptors did not influence liver stage bur-
den. Plasmodium is also capable of seizing cholesterol
produced by hepatocytes. Pharmacological blockade of
host squalene synthase (an enzyme involved in the first
step in sterol synthesis) or the down-regulation of the
expression of this enzyme by 80% diminished the choles-
terol content of merozoites without effect on parasite
development [94]. These data suggest that malaria para-
sites do need sterols for effective replication, but can
also adapt to cholesterol-restrictive conditions by using
alternative sources in hepatocytes to maintain infectivity
[94]. Another study demonstrated that HDL is essential
for the maintenance of P. falciparum in in vitro culture
[105,106]. At relatively low concentrations (0.75 mg/ml
protein) HDL is able to aid parasite growth and re-
invasion in a serum-free system. In higher concentra-
tions (2.4 mg/ml protein), HDL is toxic to the parasite
within infected erythrocytes after invasion, causing ab-
normal maturation and death of trophozoites [105]. Late
ring-stage parasites at a parasitaemia of 2% were cul-
tured with HDL or with phosphate buffer (controls). In
the HDL-treated group, unfit parasites developed with
reduced size, irregular shape, increasing stain density,
and haemozoin (malaria pigment) outside the food vacu-
ole [105]. Both host cholesterol synthesized in the endo-
plasmic reticulum as well as LDL-derived cholesterol are
co-transported to the parasitophorous vacuole. Most
probably, compensatory activity of the endogenous and
exogenous pathways to provide cholesterol to the para-
site exists. Furthermore, the parasite could also cause a
hypocholesterolaemia in malaria because it utilizes an-
other pathway, that of receptor-mediated endocytosis
[107] where cholesterol is extracted from the blood.
Host lipids in the formation of haemozoin
Besides the role of lipids in the proliferation and metab-
olism of the parasite, host lipids have also been impli-
cated in the formation of haemozoin in vivo [108,109].
Earlier, it has been shown that linoeic acid (a polyunsat-
urated fatty acid) may be necessary for the dimerization
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after the digestion of haemoglobin), the initial step in
the production of haemozoin [110]. Haemozoin is the
end product of the plasmodial detoxification of free
haem that is produced by haemoglobin degradation [20].
Historically, it was thought that haemozoin was an inert
waste product of the malaria parasite. However, recent
research resulted in the recognition of the importance of
haemozoin in different aspects of malaria [20,111,112].
Haem crystalization is the target of the widely used anti-
malarial aminoquinoline drugs [113]. Moreover, not only
does the haemozoin production require host lipids, but
it appears also that the inhibition of host monocyte
functions, one of the eminent immune-modulating hae-
mozoin effects, is caused by hydroxyl fatty acids, gener-
ated by Plasmodium spp. in large amounts in the human
hosts. The lipid hypothesis postulates that haemozoin
formation occurs most rapidly at lipid-water interfaces.
In the past 3 three years, convincing evidence is emer-
ging in favour of the lipid model. First, the lipid environ-
ments in a parasitized erythrocyte using Nile Red (a
lipophilic stain), were characterized [114]. Neutral lipids
associated with the digestive vacuole of the parasite were
observed. These were composed of di- and triacylgycer-
ols (triglycerides); possibly storage organelles for lipid
intermediates produced during the degradation of
phospholipids in the food vacuole. Mono-, di- and triac-
ylglycerol heterogeneous mixtures promote haemozoin
formation, implying that these neutral lipids are involved
in haem detoxification [114]. It was demonstrated that
triglycerides are a major lipid portion stored in lipid
droplets in the late trophozoite and schizont stage of P.
falciparum. Besides haem detoxification, it may be uti-
lized to store acryl groups for phospholipid synthesis,
glycosyl phosphatidyl inositol (a glycolipid) synthesis,
and possibly for beta-oxidation (the process by which
fatty acid molecules are broken down in the mitochon-
dria to generate acetyl-coA) [115]. Second, another study
demonstrated that in the unrelated haemozoin-forming
organisms Schistosoma mansoni, and in the kissing bug,
Rhodnius prolixus (triatomine vector of Chagas disease),
haemozoin formation occurs inside lipid droplet-like
particles or in close association to phospholipid mem-
branes (both hydrophobic environments) [116]. Third, it
has been reported that the intracellular mechanism of
molecular initiation of haemozoin formation occurs
within neutral lipid predominant nanospheres, which en-
velop haemozoin inside P. falciparum digestive vacuoles.
It was suggested that haemozoin is formed at the inter-
face between the aqueous medium of the food vacuole
and the lipid nanospheres [113]. Another study con-
firmed these findings, as molecular dynamic simulation
showed that a precursor haemozoin dimer forms spon-
taneously in the absence of the competing hydrogenbonds of water, demonstrating that this substance prob-
ably self-assembles near a lipid/water interface in vivo.
Probably, haemozoin nucleation occurs at the digestive
vacuole inner membrane, with crystallizations occurring
in the aqueous rather than lipid phase, as indicated by
cryogenic soft X-ray tomography [117-120]. Thus, lipids
mediate synthetic haemozoin formation very efficiently.
Further weight is added to this lipid hypothesis by an-
other recent study that demonstrated that haemozoin-
associated neutral lipids alone are capable of mediating
haemozoin formation at adequate rates under physiolo-
gically realistic conditions of ion concentrations to ac-
count for haemozoin formation [121]. The combination
of these recent insights makes a compelling case for the
theory that lipids drive haemozoin assembly.
Strengths and limitations
This review triangulates data from quantitative, qualita-
tive and mixed method studies to increase the content
validity and comprehensiveness of the review; however,
it does not attempt a full analysis of pathophysiological
qualitative data [122]. The meta-analysis of lipid parame-
ters was used to explore the effect of malaria between
studies and to provide a pooled analysis to support the
findings of the narrative (interpretive) synthesis.
A limitation of this meta-analysis is the statistical het-
erogeneity of the included studies [123,124]. Therefore,
random effect models were used. This was possible as
the included studies were clinically comparable (see
Additional file 7: Table S1) and on visual inspection of
the graphs the individual trial effects were in the same
direction within the majority overlapping confidence in-
tervals [125]. The statistical heterogeneity in the results
is a consequence of clinical or methodological diversity,
or both, among the included studies. In particular, the
heterogeneity may be due to differences between sub-
groups of studies. Also, data extraction errors are a com-
mon cause of substantial heterogeneity in results with
continuous outcomes [23]. However, these were mini-
mized by double-checking in the data extraction process.
Clinical variation may have resulted in heterogeneity
most obviously, patient characteristics. Also, varying pre-
cision of the measurements of lipid parameters in the in-
cluded studies can have contributed to heterogeneity,
although these are unlikely to have fully accounted for
heterogeneity in the study design. Significant statistical
heterogeneity arising from methodological diversity or dif-
ferences in outcome measurements suggests that the in-
cluded studies are not all estimating the same quantity,
but does not necessarily suggest that the true malaria ef-
fect on lipid parameters varies. In particular, heterogeneity
associated solely with methodological diversity would in-
dicate the studies suffer from different degrees of bias,
which is the case (see Additional file 3). Nevertheless, as
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comparison for the outcome triglycerides with symptom-
atic controls), there is strong evidence that on average
there are malaria-specific effects on common lipid profile
parameters.
Another limitation is the poor-to-moderate quality of
the studies included in this review, which results from the
nature of the study design (some observational studies in-
cluded healthy controls, some controls with other infec-
tious diseases and some did not include controls at all)
and incomplete reporting of essential data (randomization
procedures, etc.). However, the consistency of results
across studies and settings suggest that the findings of
lowered TC, HDL and LDL in patients with malaria are
robust.
Reference values of lipid parameters may vary widely
between countries and populations, however, they did
not influence the results since only mean differences
were used in the meta-analysis.
The probability of publication bias was judged as sub-
stantial. The funnel plots did not identify publication
bias. However, it must be noted that, as a rule of thumb,
tests for funnel plot asymmetry should be used with
confidence only when there are at least ten studies in-
cluded in the meta-analysis, because when there are
fewer studies the power of the tests is too low to distin-
guish chance from real asymmetry. This was only the
case for funnel plot 1 in the review.
For the literature review, the main limitation was the
fact that unpublished studies were not searched for,
which may have introduced bias [126]. However, by
searching clinical trial registries for ongoing or unpub-
lished studies, this risk of bias was considerably dimin-
ished [127]. Whilst no restrictions were placed on the
language of publication [128], and no studies were ex-
cluded on the basis of language, the focus of the major-
ity of the used search engines (Medline/PubMed being
the primary source of studies) to date has been on the
European family of languages, and predominantly English.
Unfortunately one record [57], published in an Indian
medical journal, could not be retrieved despite consider-
able efforts (contacting the author(s), as well as several
European libraries). This, however, does not influence the
results since the record would not have been included in
the quantitative synthesis anyway.
Conclusion
Particular serum lipid profile changes are a characteristic
feature of malaria. Several hypotheses can explain the
underlying biological mechanisms. This review highlights
the need for further research into these biological path-
ways, which can provide new knowledge on the pathogen-
esis of malaria, and thus open avenues to explore novel
anti-malarial interventions. For example, an observationalstudy relating these characteristics of the malaria-specific
pathogen-host interplay to the amount of haemozoin pro-
duced by human-pathogenic Plasmodium.
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